D.E. Shaw & Co
APLS

D.E. Shaw & Co’s Apellis Pharmaceuticals APLS Stock Holding History

D.E. Shaw & Co’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,000
Closed -$377K – 4516
2025
Q4 		$377K Hold
15,000
– – ﹤0.01% 4057
2025
Q3 		$339K Sell
15,000
-7,700
-34% -$180K ﹤0.01% 4049
2025
Q2 		$393K Sell
22,700
-15,400
-40% -$285K ﹤0.01% 3743
2025
Q1 		$833K Buy
38,100
+7,100
+23% +$196K ﹤0.01% 3201
2024
Q4 		$989K Buy
+31,000
New +$932K ﹤0.01% 3208

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's APLS Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 186,853 shares — an estimated $7.52M sold.

D.E. Shaw & Co first reported a position in APLS in Q3 2019 and held it in 23 quarters. The position peaked at $48.1M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • D.E. Shaw & Co reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 186,853 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.52M.
  • D.E. Shaw & Co first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 23 quarters.
  • D.E. Shaw & Co's Apellis Pharmaceuticals position peaked at $48.1M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.